Literature DB >> 7591208

LOH and mutation analysis of CDKN2 in primary human ovarian cancers.

I G Campbell1, W D Foulkes, G Beynon, M Davis, P Englefield.   

Abstract

The CDKN2 gene encodes a cell cycle regulatory protein and is located on chromosome 9p21, a region deleted in a wide variety of primary tumours. While mutations in the CDKN2 gene itself are frequently observed in tumour cell lines, they are less common in primary tumours. We have investigated the role of the CDKN2 gene in ovarian cancer by analysis for allelic loss of 9p21 and single-strand conformational polymorphism analysis of exons 1 and 2 of CDKN2 in 67 primary ovarian tumours. Loss of heterozygosity on 9p21 was frequently observed (24/50 informative tumours) and was common in early-stage tumours, suggesting that it is an early event in ovarian tumorigenesis. Homozygous deletion of the CDKN2 gene was detected in only 1 tumour. No somatic or germline mutations were observed in CDKN2, though a codon 140 polymorphism was detected in 2 cases. This suggests that CDKN2 is not involved in ovarian tumorigenesis and that another gene(s) may be the target of the frequent 9p allelic losses observed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591208     DOI: 10.1002/ijc.2910630213

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  The CDKN2A (p16) gene and human cancer.

Authors:  W D Foulkes; T Y Flanders; P M Pollock; N K Hayward
Journal:  Mol Med       Date:  1997-01       Impact factor: 6.354

2.  Use of laser capture microdissection allows detection of loss of heterozygosity in chromosome 9p in breast cancer.

Authors:  Margarida Figueiredo Dias; Robert Blumenstein; Jose Russo
Journal:  Oncol Lett       Date:  2017-03-22       Impact factor: 2.967

3.  Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma.

Authors:  A K El-Naggar; S Lai; G Clayman; J K Lee; M A Luna; H Goepfert; J G Batsakis
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

4.  Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours.

Authors:  S Marchini; A M Codegoni; C Bonazzi; S Chiari; M Broggini
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma.

Authors:  H Tsuda; K Yamamoto; T Inoue; I Uchiyama; N Umesaki
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

6.  CDKN2A gene inactivation in epithelial sporadic ovarian cancer.

Authors:  D Niederacher; H Y Yan; H X An; H G Bender; M W Beckmann
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

7.  Histotype-specific copy-number alterations in ovarian cancer.

Authors:  Ruby Yunju Huang; Geng Bo Chen; Noriomi Matsumura; Hung-Cheng Lai; Seiichi Mori; Jingjing Li; Meng Kang Wong; Ikuo Konishi; Jean-Paul Thiery; Liang Goh
Journal:  BMC Med Genomics       Date:  2012-10-18       Impact factor: 3.063

8.  Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours.

Authors:  M Schuyer; I L van Staveren; J G Klijn; M E vd Burg; G Stoter; S C Henzen-Logmans; J A Foekens; E M Berns
Journal:  Br J Cancer       Date:  1996-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.